STAT3 as a biomarker of progression in atypical nevi of patients with melanoma: dose-response effects of systemic IFNalpha therapy. [electronic resource]
Producer: 20080829Description: 1997-2002 p. digitalISSN:- 1523-1747
- Biomarkers, Tumor -- genetics
- Biopsy
- Disease Progression
- Dose-Response Relationship, Drug
- Gene Expression Regulation, Neoplastic
- Humans
- Immunologic Factors -- therapeutic use
- Interferon-alpha -- therapeutic use
- Melanoma -- drug therapy
- Nevus -- drug therapy
- STAT1 Transcription Factor -- genetics
- STAT3 Transcription Factor -- genetics
- Skin Neoplasms -- drug therapy
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.